Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018


Buy Now

Clinical trials are conducted in medical research labs to find better ways to prevent and treat diseases or diagnose them. They give solutions to the medical approaches suitable for certain illness to a certain group of people specifically. These trials help a great deal in making healthcare decisions. Since they answer scientific questions, these trials are required to be carried on under strict and scientific standards that protect the interests of the patients. They are also the final and the most important stage of clinical research and development. Clinical trials for drugs take place in four phases- first, they test an experimental drug on a few people and study the effects; second, they test the drug on more people than in Phase 1 which may extend up to years; third, they include many other participants to test for safety and efficacy and study the side effects deeper than in Phase 2; fourth, getting approval of the usage of drug from the relevant authority.

Progressive Supranuclear palsy, which is commonly addressed as Steele-Richardson-Olszewski syndrome, is a brain disorder that causes serious problems with walking, balance and eye movements. This disorder leads to deterioration of cells in certain parts of your brain that leads to disturbances in everyday functioning and thinking. It gets worsened by time and no cure has been discovered for this syndrome till date. However, treatments are offered to manage the symptoms and signs. The roots of progressive supranuclear palsy are unknown and do not relate to genetics. But it mostly affects people around the age of 60.

Ken Research’s Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018 gives an overview of the global clinical trials landscape and top-level data related to clinical trials by Regio, Country (G7 and E7), Trial Status, trial Phase, Sponsor type, and Endpoint status. The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company and all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for their non-accomplishments. It provides enrolment trends for the past five years and the latest news relating to these trials for the past three months. The companies involved in the clinical trials of Progressive Supranuclear palsy are AlzProtect SAS, AbbVie Inc, Biogen Inc, TauRx Pharmaceuticals Ltd, Mithridion Inc, Merz Pharma GmbH & Co KgaA, AB Science SA, Allon Therapeutics Inc., Alectos Therapeutics and Acadia Pharmaceuticals Inc. The report will enhance the decision- making capabilities and helps to create an effective counter-strategy to gain a competitive advantage.

To know more, click on the link below:

Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018

Related Reports:                                                        

Progressive Supranuclear Palsy-Pipeline Review, H1 2018

Progressive Supranuclear Palsy Global Clinical Trials Review, H2, 2016

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications